Rebecca L Rohde1, Eric Adjei Boakye2, Sai Deepika Challapalli1, Shivam H Patel1, Christian J Geneus3, Betelihem B Tobo4, Matthew C Simpson5, Kahee A Mohammed6, Teresa Deshields7, Mark A Varvares5, Nosayaba Osazuwa-Peters4,8,9. 1. Saint Louis University School of Medicine, St Louis, Missouri. 2. Saint Louis University Center for Health Outcomes Research, St Louis, Missouri. 3. Department of Biostatistics and Bioinformatics, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana. 4. Department of Epidemiology and Biostatistics, Saint Louis University College for Public Health and Social Justice, St Louis, Missouri. 5. Department of Otolaryngology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. 6. Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri. 7. Department of Medicine, Washington University School of Medicine, St Louis, Missouri. 8. Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St Louis, Missouri. 9. Saint Louis University Cancer Center, St Louis, Missouri.
Abstract
OBJECTIVE: Depression is a significant problem for patients with head and neck cancer (HNC). This study explored the prevalence of and sociodemographic and clinical factors associated with depression, among patients with HNC. METHODS: We performed a retrospective analysis of 71 541 cases of HNC using a national dataset, the Nationwide Inpatient Sample, from 2008 to 2013. Weighted, multivariate logistic regression analysis estimated association between sociodemographic/clinical factors and tumor anatomical site with diagnosis of a major depressive disorder. RESULTS: Overall prevalence of major depressive disorder in HNC was 9.3%; highest prevalence was found in patients with laryngeal cancer (28.5%). Compared with laryngeal cancer, there were lower odds of depression among patients with oral cavity cancer (adjusted odds ratio [aOR] = 0.90; 95% CI, 0.84-0.97) and other anatomic sites (aOR = 0.87; 95% CI, 0.81-0.94), except oropharyngeal cancer (aOR = 1.00; 95% CI, 0.93-1.08). For every unit increase in comorbidities, odds of depression increased by 20% (aOR = 1.20; 95% CI, 1.19-1.23). Sociodemographic factors associated with increased odds of depression included being female (aOR = 1.77; 95% CI, 1.68-1.87), white (aOR = 1.75; 95% CI, 1.59-1.92), and having Medicaid (aOR = 1.09; 95% CI, 1.01-1.19) or Medicare insurance (aOR = 1.19; 95% CI, 1.10-1.27). CONCLUSIONS: Depression odds vary depending on HNC anatomic site, and one in four patients with laryngeal cancer may be depressed. Since depression is prevalent in this survivor cohort, it is important that psychosocial assessment and intervention are integrated into mainstream clinical care for patients with HNC.
OBJECTIVE:Depression is a significant problem for patients with head and neck cancer (HNC). This study explored the prevalence of and sociodemographic and clinical factors associated with depression, among patients with HNC. METHODS: We performed a retrospective analysis of 71 541 cases of HNC using a national dataset, the Nationwide Inpatient Sample, from 2008 to 2013. Weighted, multivariate logistic regression analysis estimated association between sociodemographic/clinical factors and tumor anatomical site with diagnosis of a major depressive disorder. RESULTS: Overall prevalence of major depressive disorder in HNC was 9.3%; highest prevalence was found in patients with laryngeal cancer (28.5%). Compared with laryngeal cancer, there were lower odds of depression among patients with oral cavity cancer (adjusted odds ratio [aOR] = 0.90; 95% CI, 0.84-0.97) and other anatomic sites (aOR = 0.87; 95% CI, 0.81-0.94), except oropharyngeal cancer (aOR = 1.00; 95% CI, 0.93-1.08). For every unit increase in comorbidities, odds of depression increased by 20% (aOR = 1.20; 95% CI, 1.19-1.23). Sociodemographic factors associated with increased odds of depression included being female (aOR = 1.77; 95% CI, 1.68-1.87), white (aOR = 1.75; 95% CI, 1.59-1.92), and having Medicaid (aOR = 1.09; 95% CI, 1.01-1.19) or Medicare insurance (aOR = 1.19; 95% CI, 1.10-1.27). CONCLUSIONS:Depression odds vary depending on HNC anatomic site, and one in four patients with laryngeal cancer may be depressed. Since depression is prevalent in this survivor cohort, it is important that psychosocial assessment and intervention are integrated into mainstream clinical care for patients with HNC.
Keywords:
Nationwide Inpatient Sample (NIS); cancer; cancer survivorship; depression; gender differences; head and neck cancer (HNC); laryngeal cancer; major depressive disorder (MDD); oncology; psychosocial morbidity
Authors: Kavelin Rumalla; Michelle Lin; Elliot Orloff; Li Ding; Gabriel Zada; William Mack; Frank Attenello Journal: World Neurosurg Date: 2020-07-16 Impact factor: 2.104
Authors: Abigail S Robbertz; David M Weiss; Farrukh T Awan; John C Byrd; Kerry A Rogers; Jennifer A Woyach Journal: Support Care Cancer Date: 2019-07-22 Impact factor: 3.603
Authors: Nosayaba Osazuwa-Peters; Matthew C Simpson; Rebecca L Rohde; Sai D Challapalli; Sean T Massa; Eric Adjei Boakye Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302